Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q1FY26 results Revenue stood at Rs 756 million, up 23.1% year-on-year Operating EBITDA came in at Rs 157 million, rising 24.1% YoY EBITDA margin was 20.8%, expanding by 17 bps YoY ESOP cost was Rs 15 million, down 38.9% from Q1FY25 PAT stood at Rs 108 million, with a margin expansion of 562 bps YoY Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals said, “We have started FY 26 on a strong note with growth across all parameters. While our Revenue grew 23.1% to Rs 756 million, operating EBITDA was at Rs 157 million, up by 24.1%. The continued scale up is an outcome of our disciplined and effective execution of our strategy. Net profit for the quarter more than doubled to Rs 108 million, with addition of another Rs 153 million of free cash, which stood at Rs 1609 million as on 30th June 2025. We further strengthened our position to #7 in the Gynae CVM rankings, reinforcing our leadership in the category. We expect the growth momentum to continue as we deepen our presence in the domestic pharmaceutical market coupled with prudent use of free cash to look for a strategically suitable inorganic opportunity.“ Result PDF
Conference Call with Jagsonpal Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.